TSTickerStar
Company alerts/ARTL
ARTL company alerts

ARTL updates worth following

TickerStar monitors official filings, investor releases, earnings, and call updates for ARTL. Subscribe to ARTL alerts to receive concise, source-linked alerts when TickerStar detects a meaningful company update.

Official-source feed

Recent ARTL alert previews

TickerStar filters routine noise and surfaces investor-relevant filings, releases, earnings, and call updates.

EarningsOfficial company source

Artelo Biosciences Reports Q3 2026 Financial Results

Artelo Biosciences reported a Q3 2026 net loss of $1.8 million or $3.19 per basic and diluted common share, compared to a net loss of $3.1 million in Q3 2025. R&D expenses decreased to $0.8 million from $1.3 million year-over-year, while G&A expenses declined to $1.0 million from $1.8 million. The company ended the quarter with $4.4 million in cash.

Read source-backed brief
SEC filingSEC filing

ARTL 10-Q filed 2026-11-12 | Key takeaways

ARTL filed its 10-Q; the most relevant disclosure change is expanded Legal Proceedings: Craft Capital Management LLC filed a FINRA arbitration claim on April 7, 2026, seeking an $880,000 success fee, common stock warrants valued at $880,000, monthly late fees, attorneys' fees, interest, and other relief related to an alleged breach of a right of.

Read source-backed brief
Equity offeringSEC filing

Artelo Biosciences discloses potential Nasdaq $5M MVLS listing rule impact

Artelo Biosciences filed an 8-K under Item 8.01 disclosing that it was identified among approximately 180 Nasdaq-listed companies with a market value of listed securities below the new $5,000,000 MVLS threshold approved by the SEC on July 22, 2026. A temporary stay of the $5M MVLS Rule was announced on July 29, 2026, and on October 5, 2026 the SEC published for comment a Nasdaq proposal to modify the operative date to be upon termination of the temporary stay (comments due October 29, 2026). The Company stated i...

Read source-backed brief